Germany's Merck forges JV with Thiel's Palantir to harness data to attack cancer
With the incidence of cancer exploding in most parts of the world, harnessing the power of data has become imperative to unlocking solutions for one of the titanic public health challenges in this century. As such, Germany’s Merck KGaA has tied up with Peter Thiel’s data mining company Palantir Technologies under a joint venture called Syntropy that will allow scientists and researchers to tap into a collaborative tech platform to advance cancer research.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.